devazepide and Hyperphagia

devazepide has been researched along with Hyperphagia* in 2 studies

Other Studies

2 other study(ies) available for devazepide and Hyperphagia

ArticleYear
Cholecystokinin and hypothalamic corticotrophin-releasing factor participate in endotoxin-induced hypophagia.
    Experimental physiology, 2011, Volume: 96, Issue:4

    Cholecystokinin (CCK) provides a meal-related signal that activates brainstem neurons, which have reciprocal interconnections with the hypothalamic paraventricular nucleus. Neurons that express corticotrophin-releasing factor (CRF) in the hypothalamus possess anorexigenic effects and are activated during endotoxaemia. This study investigated the effects of CCK(1) receptor blockade on lipopolysaccharide (LPS)-induced hypophagia and hypothalamic CRF neuronal activation. Male Wistar rats were pretreated with a specific CCK(1) receptor antagonist (devazepide; 1 mg kg(-1); i.p.) or vehicle; 30 min later they received LPS (100 μg kg(-1); i.p.) or saline injection. Food intake, corticosterone responses and Fos-CRF and Fos-α-melanocyte-stimulating hormone (α-MSH) immunoreactivity in the hypothalamus and Fos-tyrosine hydroxylase immunoreactivity in the nucleus of the solitary tract (NTS) were evaluated. In comparison with saline treatment, LPS administration decreased food intake and increased plasma corticosterone levels, as well as the number of Fos-CRF and Fos- tyrosine hydroxylase double-labelled neurons in vehicle-pretreated rats; no change in Fos-α-MSH immunoreactivity was observed after LPS injection. In saline-treated animals, devazepide pretreatment increased food intake, but it did not modify other parameters compared with vehicle-pretreated rats. Devazepide pretreatment partly reversed LPS-induced hypophagia and Fos-CRF and brainstem neuronal activation. Devazepide did not modify the corticosterone and Fos-α-MSH responses in rats treated with LPS. In conclusion, the present data suggest that LPS-induced hypophagia is mediated at least in part by CCK effects, via CCK(1) receptor, on NTS and hypothalamic CRF neurons.

    Topics: alpha-MSH; Animals; Brain Stem; Cholecystokinin; Corticosterone; Corticotropin-Releasing Hormone; Devazepide; Eating; Endotoxemia; Endotoxins; Hyperphagia; Hypothalamus; Lipopolysaccharides; Male; Neurons; Paraventricular Hypothalamic Nucleus; Pituitary Hormone-Releasing Hormones; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptor, Cholecystokinin A; Solitary Nucleus; Tyrosine 3-Monooxygenase

2011
Lack of interaction between devazepide and 8-OH-DPAT-induced hyperphagia in the rat.
    Physiology & behavior, 1996, Volume: 60, Issue:5

    Recently, a number of studies have provided evidence suggesting that CCK and 5-HT interact in the control of food intake. However, the majority of these studies have relied on the administration of exogenous CCK to investigate potential interactions. The aim of the present study was to focus on the potential role of endogenous CCK in 5-HT-CCK interactions. Our prediction was that the CCKA antagonist, devazepide, alone would potentiate the hyperphagic effect of the 5-HT1A agonist, 8-OH-DPAT, in free-feeding rats. The results showed that devazepide, at a dose that had no intrinsic effect (1.0 mg/kg), did not enhance the hyperphagic effect of 8-OH-DPAT (100 and 300 micrograms/kg). This suggests that when serotonergic inhibitory activity is reduced by 5-HT1A-receptor stimulation, there is no compensatory increase of endogenous CCK activity to excite 5-HT neurons and thereby inhibit food intake.

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzodiazepinones; Devazepide; Drug Interactions; Eating; Hormone Antagonists; Hyperphagia; Male; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Serotonin Receptor Agonists

1996